In AMLs, aberrant SALL4 has also been shown to block all-trans retinoic acid (ATRA)-mediated myeloid differentiation in both ATRA-sensitive and ATRA-resistant AML subtypes [62]. Here, SALL4 is linked to acute myeloid leukemia.